{Reference Type}: Journal Article
{Title}: In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model.
{Author}: Gopalappa R;Lee M;Kim G;Jung ES;Lee H;Hwang HY;Lee JG;Kim SJ;Yoo HJ;Sung YH;Kim D;Baek IJ;Kim HH;
{Journal}: Mol Ther
{Volume}: 32
{Issue}: 7
{Year}: 2024 Jul 3
{Factor}: 12.91
{DOI}: 10.1016/j.ymthe.2024.05.027
{Abstract}: X-linked adrenoleukodystrophy (ALD), an inherited neurometabolic disorder caused by mutations in ABCD1, which encodes the peroxisomal ABC transporter, mainly affects the brain, spinal cord, adrenal glands, and testes. In ALD patients, very-long-chain fatty acids (VLCFAs) fail to enter the peroxisome and undergo subsequent β-oxidation, resulting in their accumulation in the body. It has not been tested whether in vivo base editing or prime editing can be harnessed to ameliorate ALD. We developed a humanized mouse model of ALD by inserting a human cDNA containing the pathogenic variant into the mouse Abcd1 locus. The humanized ALD model showed increased levels of VLCFAs. To correct the mutation, we tested both base editing and prime editing and found that base editing using ABE8e(V106W) could correct the mutation in patient-derived fibroblasts at an efficiency of 7.4%. Adeno-associated virus (AAV)-mediated systemic delivery of NG-ABE8e(V106W) enabled robust correction of the pathogenic variant in the mouse brain (correction efficiency: ∼5.5%), spinal cord (∼5.1%), and adrenal gland (∼2%), leading to a significant reduction in the plasma levels of C26:0/C22:0. This established humanized mouse model and the successful correction of the pathogenic variant using a base editor serve as a significant step toward treating human ALD disease.